ET Inhibitors

Endothelins (ETs) are a family of peptides known to play pivotal roles in a range of physiological processes. These peptides exert their effects primarily through their interactions with specific receptors known as endothelin receptors. Given the importance of the endothelin signaling pathway, there has been significant interest in understanding the compounds that can modulate this pathway. ET inhibitors specifically target and modulate the activity of this system, either by inhibiting the synthesis or action of endothelins or by blocking their receptors. ET inhibitors can be classified based on their mechanism of action. Firstly, there are those that inhibit the synthesis of endothelins. These compounds target the enzymes responsible for the production of endothelins, such as endothelin-converting enzyme (ECE). By inhibiting this enzyme, they reduce the levels of active endothelin peptides. Another group of ET inhibitors are those that block the endothelin receptors directly. The endothelin system consists of two primary receptor subtypes: ETA and ETB. Compounds in this category can be selective for one receptor subtype over the other, or they can be non-selective, targeting both receptor types. The selectivity of an inhibitor towards a particular receptor subtype can have significant implications for its overall effect on the endothelin signaling pathway. The intricate balance between the activities of these receptors can dictate the ultimate physiological response, making the specificity of ET inhibitors crucial in understanding their action at the molecular level.